Prognostic alternative splicing signature in cervical squamous cell carcinoma
Prognostic alternative splicing signature in cervical squamous cell carcinoma
复制标题
宫颈鳞状细胞癌的预后选择性剪接特征
DOI：
10.1049/iet-syb.2019.0095
复制
发表时间：
2020-12-01
影响因子：
2.3
通讯作者：
Pan，Shang-ling
中科院分区：
文献类型：
--
作者：
Wu，Hua-yu;Li，Qi-qi;Pan，Shang-ling
基于选择性剪接事件（ASES）数据库，作者旨在探索宫颈鳞状细胞癌（CESC）的潜在预后生物标志物。从癌症基因组图谱（TCGA）中获得223例CESC患者的mRNA表达谱和相关临床资料。相关基因、ASE和剪接百分比（PSI）分别从SpliceSeq下载。生存相关可变剪接事件（SASE）的PSI值用于构建预后指数（PI）的基础。利用STRING技术构建了SASE相关基因的蛋白质相互作用（PPI）网络，并利用基因本体（GO）和京都基因与基因组百科全书（KEGG）进行了分析。结果，在19,724个基因中发现了41,776个ASE，其中2596个与3669个SASE连锁。SASE相关基因的PPI网络显示TP 53和UBA 52为核心基因。低风险组的生存期长于高风险组，两组均根据前20个剪接事件构建的PI或总体剪接事件的PI定义。ROC曲线的AUC值达到0.88，表明PI在CESC中的预后潜力。这些结果表明，ASES参与了CESC的发病机制，并可能作为这种女性恶性肿瘤的有希望的预后生物标志物。
Basing on alternative splicing events (ASEs) databases, the authors herein aim to explore potential prognostic biomarkers for cervical squamous cell carcinoma (CESC). mRNA expression profiles and relevant clinical data of 223 patients with CESC were obtained from The Cancer Genome Atlas (TCGA). Correlated genes, ASEs and percent‐splice‐in (PSI) were downloaded from SpliceSeq, respectively. The PSI values of survival‐associated alternative splicing events (SASEs) were used to construct the basis of a prognostic index (PI). A protein–protein interaction (PPI) network of genes related to SASEs was generated by STRING and analysed with Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Consequently, 41,776 ASEs were discovered in 19,724 genes, 2596 of which linked with 3669 SASEs. The PPI network of SASEs related genes revealed that TP53 and UBA52 were core genes. The low‐risk group had a longer survival period than high‐risk counterparts, both groups being defined according to PI constructed upon the top 20 splicing events or PI on the overall splicing events. The AUC value of ROC reached up to 0.88, demonstrating the prognostic potential of PI in CESC. These findings suggested that ASEs involve in the pathogenesis of CESC and may serve as promising prognostic biomarkers for this female malignancy.